Neurocrine Biosciences Q3 2026 Earnings Report

Neurocrine Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: $2.59
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Neurocrine Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.04 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Neurocrine Biosciences Announcement Details

• Quarter: Q3 2026
• Date: 10/27/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, October 27, 2026
• Conference Call Time: 4:30PM ET

Neurocrine Biosciences (NASDAQ:NBIX) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and related disorders. The company is headquartered in San Diego, California, and conducts research through internal programs and collaborations with academic institutions and other pharmaceutical companies.

Neurocrine’s principal commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington’s disease. The company also markets ONGENTYS (opicapone), an adjunctive treatment for “off” episodes in adults with Parkinson’s disease receiving levodopa and carbidopa. Its portfolio has also included therapies developed through partnerships, such as elagolix, which was commercialized by AbbVie for certain women’s health conditions.

Founded in 1992, Neurocrine has built its business around treatments for conditions with significant unmet medical needs. In 2024, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) as an adjunctive treatment to glucocorticoid replacement therapy for adults and children with classic congenital adrenal hyperplasia. The company primarily serves the U.S. market while pursuing international commercialization through regional partners and license agreements.

Neurocrine is led by Chief Executive Officer Kyle Gano, who has held leadership positions with the company since joining in 2011.